INTRODUCTION

Precision medicine is defined as the selection of targeted therapies based on an improved understanding of the genetic basis of disease.\(^1\) Due to the increasing feasibility of sequencing tumor genomes at affordable costs, genome-driven oncology appears to be within grasp to improve the clinical management of patients with cancer.\(^2,3\) However, at present precision oncology has yet to prove that it can fulfill its promises and produce long-lasting remission and extend survival.\(^4,5\) Challenges include the enormous biological and clinical complexity of cancer, which is further complicated by the significant intratumor heterogeneity,\(^6\) and the impact of the tumor microenvironment.\(^7\) Furthermore, genomes of cancer cells are unstable and may frequently acquire novel changes.\(^8\)

"Liquid biopsies" are based on the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or tumor-derived extracellular vesicles, which have been shed from tumors and their metastatic sites into the blood. Multiple studies have described how molecular information about parent tumors can be extracted from liquid biopsies and a number of comprehensive reviews were recently published on CTCs,\(^9\) ctDNA,\(^10\) ctDNA,\(^11\) and extracellular vesicles,\(^12\) respectively.

Our own previous work has focused on the assessment and evaluation of somatic copy number changes as well as mutations from CTCs and ctDNA\(^13\) and has mostly been done—as the majority of other studies—at advanced disease stages. However, there are increasing efforts by us and many others to move to early disease stages. Perhaps the most ambitious efforts to this end are being conducted by GRAIL, a company that describes its mission as “detecting cancer early, when it can be cured” (https://grail.com). This ambitious aim is supposed to be accomplished by strategies including ultra-broad and ultra-deep sequencing, bioinformatics, and large population-based clinical studies.\(^34\)

Indeed, as cancer is caused by a sequential series of alterations in specific cancer genes that affect the function of certain pathways and usually takes several decades to develop, the vast majority of cancers are not detected in the first 90% of the cancers’ lifetimes.\(^35\) Due to the increasing knowledge about the driver genes involved and the pathways causing cancer, the question arises whether liquid biopsies may enable novel strategies for early diagnosis. We will focus in this review on this question and to this end we discuss the appertaining biological and technical issues related to identifying small alterations in a complex biological structure such as the human body.

PLASMA DNA DIAGNOSTICS IN PHYSIOLOGIC AND PATHOLOGIC CONDITIONS

The first description of tumor DNA in the circulation of patients with cancer\(^36\) preceded the first report about fetal DNA in blood of pregnant females\(^37\) by several years. However, reliable diagnostic tests were first established for circulating fetal DNA\(^38\) and testing for fetal aneuploidies from blood of pregnant females, referred to as non-invasive prenatal testing (NIPT), rapidly evolved to a frequently used test capable of detecting trisomies for chromosomes 13, 18, and 21 with high specificity and sensitivity.\(^39\) In contrast, the development of liquid biopsies for applications in patients with cancer has been much more arduous and several reasons account for this. Pregnancy is a highly reproducible physiological process with minor variabilities and starting from week 9 of pregnancy, the percentage of fetal DNA in the mother’s circulation is relatively high at 10%\(^40\) (Fig. 1a). In fact, with current NIPT technologies a fetal DNA concentration below 4% in maternal plasma is already considered to be prone to result in false negative results.\(^41\) In contrast, cancer is a pathologic process and a complex, heterogeneous and dynamic disease involving...
multiple gene-environment interactions affecting numerous biological pathways with multiple variables, such as tumor entity, disease stage or tumor burden, microenvironment, multiple unknown determinants of ctDNA release, and many more (Fig. 1b). As a consequence, the number of mutant DNA fragments can considerably vary and are frequently below 4%, even among patients with the same disease stage.42 Hence, ctDNA analysis is much more difficult to standardize, in particular for the detection of early disease stages as outlined in the following.

IS EARLY TUMOR DETECTION BENEFICIAL AT ALL?

A current belief is that early detection of cancer saves lives and that the earlier a tumor is diagnosed, the better the chance of survival. As this belief was not even shattered by reports that early screening did not prove to be a lifesaver in tumor entities such as those originating from thyroid, prostate and breast, Nature listed in a recent editorial “Screening saves lives for all types of cancer” that this is one of the science myths that will not die.43 We discuss the different facets of screening with breast and colon cancer as examples. A recent breast cancer study on screening mammography conducted among women 40 years of age or older revealed a large increase in the incidence of small tumors (<2 cm) and a modest decrease in the incidence of large tumors (≥2 cm).44 However, small cancers with favorable molecular features (i.e., grade 1) may have lead times, i.e., the length of time between when a cancer can be detected by screening and when it would have become clinically apparent without screening, of more than 19 years45 and are therefore often not destined to progress to large tumors within the lifetime of the patient (Fig. 2a). These tumors contribute substantially to the overall rate of overdiagnosis by screening, which was estimated to be as high as 22%.44 Furthermore, these tumors still have an excellent prognosis after progression and can be treated effectively at clinical presentation, thereby offering little benefit to detecting them early.

In contrast, the prognosis for tumors with unfavorable biologic features (i.e., grade 2–3) is considerably better if they can be diagnosed when under 2 cm in size. Unfortunately, because of their short lead times (<0.1–2.0 years45), they are rarely diagnosed early and therefore are substantially underrepresented among small tumors (Fig. 2a). Overall, the reduction in breast cancer mortality after the implementation of screening mammography was not attributed to screening but to improved systemic therapy.44 Of note, there are exceptions, as breast cancer screening for carriers of BRCA1 and BRCA2 germline mutations is recommended and surveillance programs with proven efficiency exist.46 However, screening is clearly associated with a reduction in colorectal cancer (CRC) mortality. In the US, a nearly 50% decrease in CRC incidence and mortality is attributed to screening47 and, vice versa, 63% of CRC deaths may be due to lack of screening.46
The importance of screening and early detection is also reflected in the stage-dependent survival rates in CRCs, which are 94, 82, 67, and 11% for stages I, II, III, and IV, respectively (Fig. 2b). Important biological differences between breast and colon cancer may explain the disparities in screening efficiency. There is evidence that low-grade and high-grade breast cancers arise by different molecular mechanisms and it is very rare for a low-grade tumor to dedifferentiate into a high-grade tumor. In contrast, CRC begins with the growth of adenomatous or sessile serrated polyps and the majority of polyps become dysplastic through one of two major pathways, i.e., chromosomal or microsatellite instability, and subsequently develops into malignancy so that virtually all stage IV colon cancers start out as stage I cancers (Fig. 2b).

Hence, screening may be particularly efficient in cancer types with well-defined precursor stages that would transform with a high likelihood into malignant disease. In CRC, a liquid biopsy early detection screening test would have to compete and eventually outperform established screening methods, such as guaiac-based fecal occult blood testing, fecal immunochemical test, sigmoidoscopy or colonoscopy. In breast cancer, such a liquid biopsy test would have to be informative regarding the biology of a lesion, i.e., favorable or not, in order to reduce the aforementioned rate of overdiagnosis and would then offer advantages compared to screening mammography. However, despite our knowledge about the probabilistic fate of a population of lesions observed in specific patient cohorts, it remains important for individual risk estimates to determine the biology of lesions in the context of competing causes of morbidity or mortality in the respective patient. This will be of importance in light of the growing recognition that “clonal expansions” of cells are not a rare phenomenon as outlined in the next section.

MOSAICISM AND CLONAL EXPANSION PHENOMENA

Somatic mutations increase with age and accrue at higher rates in fast renewing tissues. Mutations in adult stem cells have an especially large impact on the mutational load of tissues because of their potential for self-renewal and capacity to propagate mutations to their daughter cells. In fact, using cells capable of forming long-term organoid cultures to determine genome-wide mutation patterns in single adult stem cells from the small intestine, colon and liver, a high mutation rate of around 36 mutations per year was found. Based on these data, it is not surprising that an extensive analysis of 140 benign tissue samples representing nine solid tissues (bladder, breast, head and neck, liver, lung, prostate, stomach and thyroid), and corresponding blood revealed multiple exonic mutations in 80% of these
samples. Importantly, the cell of origin analysis indicated that many of the mutations detectable at tissue-level resolution were acquired in the long-lived tissue stem or progenitor cells.

If a mutation occurs in a driver gene, it can confer a fitness advantage which allows this cell to expand and to form a group of identical daughter cells. Ample evidence for the existence of such clonal mosaicism has been reported.

More recently, clonal expansions due to a mutation in a driver gene, which may be also associated with myelodysplasia or leukemia, such as DNMT3A, TET2, or ASXL1, and which enable a hematopoietic stem cell to expand clonally, have been extensively documented. As a consequence, these somatic mutations become detectable in blood-derived DNA with different variant allele frequencies (VAFs). These VAFs may range from 0.008 to 0.1, which corresponds to 1.6–20% of nucleated cells in circulating blood being derived from mutant hematopoietic stem cells. These observations resulted in the definition of a clonal hematopoiesis of indeterminate potential, which refers to the detection of at least one driver mutation in one of the aforementioned genes with a VAF ≥ 0.02 without overt hematologic disease, and represents a pre-cancerous condition with a risk of progressing to leukemia of 0.5–1% per year (Fig. 2c).

A recent study refined the prevalence of clonal hematopoiesis, as driver mutations were observed with exponential increase with age (20–29 years: 2.5%; 30–39 years: 3.2%; 40–49 years: 8.2%; 50–59 years: 13.2%; 60–69 years: 20.6%). The increase in prevalence and number of driver mutations was not linear, suggesting that age associated factors may accelerate the occurrence of driver mutations over time.

For solid organs, evidence for such clonal expansion is more difficult to establish as appropriate tissue is more difficult to assess, but evidence for clonally expanded cell populations has been reported for skin, ovarian cells, and brain. Such clonal expansions of apparently benign tissues may also be associated with cancer gene somatic mutations as, for example, recently shown in endometriosis. This occurrence of cancer-associated mutations in benign tissue can pose challenges for early detection of malignancies using liquid biopsy. This was shown in a recent study which used an assay specifically designed to accurately detect TP53 mutations at very low allelic fractions, in which cfDNA TP53-mutated fragments were found in 11.4% of 123 matched non-cancer controls.

THE THREE EARLY CANCER DETECTION SCENARIOS

Recent studies suggested that millions of cells are needed in order for mutations to become detectable in the peripheral blood. Even then, detectable somatic mutations often have low VAFs, but appropriate technologies employing massively parallel sequenced-fragmented technologies, molecular barcodes, and sophisticated bioinformatics strategies enable the detection of such rare DNA fragments in the circulation, with VAFs as low as 0.0025% (2.5 in 10⁵ molecules). With these requirements in mind, we next address the question whether early detection of cancer by liquid biopsy may be possible at this end we distinguish three scenarios (Fig. 3). Furthermore, we summarize specific distinctions and challenges of liquid biopsy technologies whether they are applied to pre-malignant lesions and earlier neoplastic stages versus advanced cancers in Table 1.

The first scenario relates to the detection of relapse or recurrence after surgery with curative intent (Fig. 3a). Here, the options for ctDNA profiling to detect relapse are excellent for two reasons. First, the presence of ctDNA after tumor resection has been shown to indicate evidence of residual disease and hence points to high risk of recurrence in patients with early breast cancer receiving neoadjuvant chemotherapy, with stage II colon cancer, and with non-small-cell lung cancer (NSCLC). Hence, ctDNA testing may be capable of identifying patients in need of very close monitoring. Second, detailed characterization of the resected primary tumor allows the design of patient-specific assay panels and the development of personalized markers. To this end, taking leverage of somatic structural rearrangements, e.g., translocation breakpoints, yields biomarkers with high sensitivity and specificity, as these aberrant fusions of DNA sequences do not occur in non-tumor cells. Another option is the aforementioned barcoding strategy combined with the simultaneous testing of a large number of mutations and the use of a threshold for a minimum number of mutations needed to be detected for a plasma sample to be called tumor-positive. These strategies have been shown to detect relapse with lead time compared to...
| Parameter                                      | Precancers/early stages                                      | Advanced cancers                                      |
|------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------|
| Size of lesion                                 | Usually small (< 1 cm³)                                     | Large (≥ 1 cm³)                                        |
| Clinical signs                                 | Usually none                                                | Apparent                                              |
| Detectable by imaging                          | Often not detectable                                         | Yes                                                   |
| Biology of lesion                              | May range from favorable to unfavorable (refs. 44, 45)       | Advanced cancers have in general unfavorable (sub)clones (ref. 6) |
| Presence of established other tumor markers (e.g., PSA, CEA, CA 125) | Uncertain (ref. 129)                                         | Frequently available, but without high specificity/sensitivity; useful for disease monitoring (ref. 129) |
| Knowledge of genes to be targeted in liquid biopsy assays | Often unknown (refs. 78, 80)                                | Usually known or can be established from available tumor tissue (refs. 3, 35, 73) |
| Established driver genes                       | Often unknown (refs. 130, 131)                              | Usually known (refs. 3, 35)                           |
| Release of tumor DNA into the circulation      | Uncertain (refs. 42, 80)                                    | At stage III and IV disease close to 100% of patients (ref. 42) |
| Applicable plasma DNA technologies             | Usually focused high-sensitivity assays (refs. 16–18)       | Broad range of targeted and untargeted approaches (refs. 16–18) |
| Option of proximal sampling                    | Only if endangered tissue is known (refs. 16, 17)           | In selected tumor entities, but frequently not necessary |
| Option to design personalized assays           | Possible, provided that tissue is available (refs. 73, 84, 85) | Tissue is usually available, can be designed for truncal and branch mutations (refs. 73) |
| Expected VAF of somatic mutations in blood     | Extremely low, if present at all (refs. 42, 80)             | Frequently high (refs. 32, 42, 107, 132)              |
| Tumor heterogeneity                            | Relatively low (refs. 6, 133)                               | High (refs. 6, 133)                                   |
| Presence of potentially confounding mutations | In particular, persons with increased age may have acquired cancer-associated mutations without ever developing cancer (refs. 65, 71, 72) | Distinction between driver and passenger mutations needed for disease monitoring (ref. 35) |
| Presence of potentially confounding clones     | Clonal expansion of non-tumorous tissue may mimic a malignant event (refs. 65, 67–70) | Likely that all metastatic sites are reflected in plasma DNA analysis (ref. 134) |
| Detection of SCNAs                              | Hard to detect due to low VAF at this disease stage (refs. 23, 27) | Often informative and may indicate evolution of novel clones (ref. 32) |
| Availability of established clinical guidelines | None                                                        | Emerging e.g., EGFR mutation testing as blood-based companion diagnostic for patients with NSCLC |

PSA prostate-specific antigen, CEA carcinoembryonic antigen, CA 125 cancer antigen 125, VAF variant allelic frequency, SCNAs somatic copy number alterations, NSCLC non-small-cell lung cancer
standard techniques. However, a present drawback is that no clinical guidelines for handling plasma DNA-based information exist yet. For example, breakpoint mutant DNA molecules may be detected at levels as low as 0.001%.\textsuperscript{84} If a follow-up analysis reveals an increase of such a patient-specific marker from 0.001% to—let’s say—0.05% in the plasma DNA, but standard imaging does not show evidence for relapse, there are no guidelines whether and how this should affect the clinical management of the respective patients. Furthermore, the early detection and characterization of potential disease recurrence at the genomic level would help stratify patients who might benefit from a particular adjuvant regimen and would provide a platform for tracking adjuvant treatment response. For example, in patients with stage II colon cancer treated with adjuvant chemotherapy, the persistent presence of ctDNA after therapy indicated a reduced recurrence-free survival.\textsuperscript{83} Similarly, it was reported that in NSCLC patients in-depth characterization of postoperative plasma allows identification of adjuvant chemotherapy resistance and hence patients with a high likelihood for disease recurrence.\textsuperscript{73}

The second scenario includes screening of at-risk persons (Fig. 3b), i.e., due to a hereditary predisposition, such as germline mutations in \textit{BRCA1} or \textit{BRCA2}, or in a mismatch-repair gene predisposing to Lynch syndrome, or because of chronic exposure to toxic agents, e.g., smokers with their increased risk for lung cancer, or due to viral infections. In any case, due to the known risk pattern, pre-knowledge exists which can be leveraged to tailor screening tests for specific organs. In such cases, sensitivity can be improved by extending analyses beyond blood samples by additionally sampling other body fluids or cytological specimens which are close to the organ at risk. Pioneering studies have already shown several decades ago that tumor-specific mutations can be identified in urine of patients with bladder cancer\textsuperscript{88} and in the stool of patients with curable CRC.\textsuperscript{89} This strategy, which has also been referred to as “proximal sampling,”\textsuperscript{16} has recently been extensively employed for the detection of mutations associated with ovarian cancer in ovarian cyst fluids,\textsuperscript{90} from lavage of the uterine cavity\textsuperscript{91} from tampons,\textsuperscript{92} or from Papanicolaou (Pap) smears.\textsuperscript{93} Other examples include the analysis of saliva for the detection of head and neck squamous cell carcinomas\textsuperscript{94} or cerebrospinal fluid to obtain information about brain and spinal cord tumors.\textsuperscript{95,96} Hence, pre-knowledge about endangered organs significantly extends options for analyses which may significantly facilitate early detection efforts. Regarding cancer entities associated with viral infections, a recent study reported that screening for Epstein-Barr virus (EBV) DNA in plasma allows the detection of early asymptomatic nasopharyngeal carcinoma.\textsuperscript{97} A high specificity was achieved by focusing on a target sequence, which is repeated about ten times within the EBV genome. As each nasopharyngeal tumor cell contains approximately 50 EBV genome copies, the target sequence is actually present about 500 times in each cell, which greatly facilitates its detection when released into the circulation. Furthermore, to distinguish EBV signals from infections, the investigators repeated the evaluation after 4 weeks to identify those individuals with persistent positive results.\textsuperscript{97} Conducting this study in an endemic area, a positive predictive value (PPV) of 11% was achieved; however, this PPV may drop if such a screening is conducted outside of endemic areas or high-risk persons.\textsuperscript{97,98} Nevertheless, this study illustrates that plasma DNA screening may allow early detection of cancers associated with viral infections.

The third scenario is the toughest group, i.e., the general population, where no pre-knowledge about the individual risk or organs at risk exists, i.e., there is no clue as to where to search and what to look for (Fig. 3c). Due to the lack of tumor material, patient-specific assays cannot be designed for screening and proximal sampling strategies will likely be insufficient without any knowledge regarding at-risk organs. Furthermore, as outlined above, phenomena such as the occurrence of mutations in driver genes in non-tumorous tissue and clonal expansions will likely be reasons as to why approaches based on mutation screening alone will be insufficient. Hence, it is likely that more robust results can be achieved by other liquid biopsy strategies.

In addition to these three main early detection scenarios, the early detection of resistant clones is clinically of utmost importance. Although targeted therapies have expanded upon cancer treatment options over the last decade, the tumor heterogeneity and complexity of clonal evolution and selection discussed previously almost inevitably lead to the development of resistance to systemic treatment in a large number of tumors. Various landmark studies have already exemplified the use of ctDNA to make temporal measurements of total tumor burden and to identify the presence of mutations conferring resistance to therapy with considerable lead time compared to routinely used imaging procedures.\textsuperscript{31,42,74,99–102} Not only can this approach help detect prevalent mutations with known associations of acquired resistance, but it can also indicate the presence of novel associated mutations and offer new insight into their role in the buildup to resistance, as was demonstrated by the development of NRAS codon 61 mutations in 62.5% of profiled CRC patients progressing after EGFR blockade.\textsuperscript{32} Since newly detected clones in the circulation may derive from minor pre-existing clones originating in the primary tumor\textsuperscript{14} as well as from ongoing mutagenesis, it has been suggested that multiple resistance mechanisms may exist simultaneously, thus highlighting the need to monitor the change in clonal burden with time.\textsuperscript{102}

**FUTURE LIQUID BIOPSY EXTENSIONS**

As mentioned above, more robust results can likely be achieved, in particular for 3rd scenario cases, by extended liquid biopsy strategies involving more parameters. Such alternative strategies include the extraction of additional information from plasma DNA and furthermore by combining analyses of various other components. Additional information from plasma DNA can be obtained by bisulfite sequencing and methylation deconvolution of the sequencing data, which may provide information about the tissue of origin of the plasma DNA.\textsuperscript{93–105} Furthermore, as plasma DNA is nucleosome-protected DNA, nucleosome-position maps can be directly established from cfDNA, which can also inform about the tissue of origin\textsuperscript{106} or even provide information about the expression status of genes from the cells which released their DNA into the circulation.\textsuperscript{107}

An intensely debated issue is the plasma DNA fragment size,\textsuperscript{108} as recent studies have demonstrated that ctDNA is shorter than cfDNA from non-tumor cells.\textsuperscript{109,110} Therefore, there are extensive efforts to increase the proportion of smaller (<100 bp) cfDNA fragments either by different DNA library preparation protocols\textsuperscript{106,111} or excision of DNA with appropriate size patterns from polyacrylamide gels.\textsuperscript{110} Whether these efforts result in an enrichment of a specific plasma DNA subpopulation and may hence increase resolution is a matter of debate at present.\textsuperscript{110,112,113}

However, options for combination strategies appear to be almost endless, as peripheral blood contains a number of other components released by cells into the circulation, such as mRNA, miRNA, extracellular vesicles, proteins or cancer metabolites. Since several of these additional components released into the circulation have gained much recent attention regarding their clinical utility for supplementing the liquid biopsy, they will be addressed here briefly.

The “circulating transcriptome”, which encompasses miRNAs, lncRNAs and mRNAs, could provide additional clinical value in assessing tumor-specific changes. The presence of circulating tumor-derived mRNA may allow the identification of tumor-specific gene expression profiles (reviewed in refs. 17, 21, 114). However, extracellular mRNA proves difficult to detect in the circulation, as the majority of these molecules are promptly
degraded by RNase activity. In contrast, miRNAs demonstrate remarkable stability in blood and are also known to circulate in the protected form of exosomes, which are microvesicles carrying functional biomolecules that can be transferred horizontally to recipient cells. Furthermore, tumor-educated platelets were recently identified as another source for miRNAs. As miRNA signatures in blood appear to reflect the miRNA pattern from the corresponding tumor, it is likely that miRNAs will remain at the forefront of biomarker research due to their accessibility and diagnostic potential. Furthermore, IncRNAs, another class of noncoding RNAs which are greater than 200 nucleotides in length, are also stable in blood, as they are protected from endogenous RNases. Although they have not been studied as extensively as miRNAs, circulating IncRNAs may evolve to noninvasive biomarkers for tumor diagnosis.

The potential of proteomic applications for the early detection of cancer has been explored for a long time, but many protein-based tests have not reached the sensitivity and specificity needed in clinics. Recent advances in proteomics and peptidomics have provided novel means for adding such molecules to the arsenal of the liquid biopsy approach. Some studies utilized exosomes, as they contain not only nucleic acids but also proteins and some of these proteins may be exclusively present in cancer exosomes. An example is the membrane-anchored protein Gypican-1, whose occurrence in circulating exosomes was reported to allow the detection of early stages of pancreatic tumors. In addition to exosome-related proteins, blood-based protein tests were developed for a variety of tumor entities, e.g., for prostate cancer detection, combinations of total and free prostate-specific antigen levels with other biomarkers were applied. Furthermore, protein analyses were applied to other body fluids such as urine to discriminate between healthy individuals and individuals with renal cell carcinoma with high specificity and sensitivity or to distinguish urothelial carcinoma patients with non-muscle and muscle-invasive subtypes.

From such new developments, novel multi-marker panel assays may evolve with suitable sensitivity and specificity for clinical application. Hence, it is very likely that future liquid biopsy strategies aiming at early detection will encompass a multitude of different parameters and that such multiparametric analyses may change current views about resolution limits.

CONCLUSIONS
We outline here the enormous biological and technical challenges which liquid biopsies have to meet to detect precursor lesions or early cancer stages. At present, there is still no general concept describing an approach for early detection of cancer with liquid biopsies, but multiple unexplored options remain to be tested. Critical questions that must be addressed to advance the field of liquid biopsies applied toward “earlier” detection are summarized in Table 1. Aside from outstanding technical issues, one of the most important biological issues remains to be the currently unknown biology of ctDNA release, and in terms of clinical applications—due to the lack of experience and appropriate studies—the missing clinical guidelines. Importantly, we may have to adjust our perception regarding the success of early cancer detection strategies. For the reasons outlined in this review, it is unlikely that a liquid biopsy-based test will ever achieve early detection with a 100% specificity and sensitivity and there will probably be no test capable of detecting all tumor entities. However, a test which may enable early detection to a certain percentage for a subset of cancers could already have a great impact on the life of many individuals.

Data availability
Data sharing not applicable to this article as no datasets were generated.

ACKNOWLEDGEMENTS
The work in our laboratory is supported by CANCER-ID, a project funded by the Innovative Medicines Joint Undertaking (IMI JUL), by Servier, the Austrian National Bank (ONB, grant# 16917), the Austrian Science Fund (FWF, grant# P28949-B28), and by the BioTechMed-Graz flagship project “EPiAGE”. Support: The work in our laboratory is supported by CANCER-ID, a project funded by the Innovative Medicines Joint Undertaking (IMI JUL), by Servier, the Austrian National Bank (ONB, grant# 16917), the Austrian Science Fund (FWF, grant# P28949-B28), and by the BioTechMed-Graz flagship project “EPiAGE”.

AUTHOR CONTRIBUTIONS
M.R.S. authored majority of the manuscript, the other authors contributed various sections of this review as well as overall editing. In addition, E.H. contributed the figures to the review. All authors approved the final version.

ADDITIONAL INFORMATION
Competing interests: The authors declare that they have no competing financial interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Ashley, E. A. Towards precision medicine. Nat. Rev. Genet. 17, 507–522 (2016).
2. Hyman, D. M., Taylor, B. S. & Baselga, J. Implementing genome-driven oncology. Cell 168, 584–599 (2017).
3. Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1533–1538 (2011).
4. Prasad, V., Fojo, T. & Brada, M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 17, e81–e86 (2016).
5. Alix-Panabieres, C. & Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479–491 (2016).
6. Huber, D. A. & Velculescu, V. E. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 4, 650–661 (2014).
7. Yu, M., Stott, S., Toner, M., Maheshwaran, S. & Haber, D. A. Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol. 192, 373–382 (2011).
8. Heitzer, E., Ulz, P., Geigl, J. B. & Speicher, M. R. Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. Mol. Oncol. 10, 494–502 (2016).
9. Diaz, L. A. Jr & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014).
10. Heitzer, E., Ulz, P., Geigl, J. B. & Speicher, M. R. The biology of circulating tumor cells. Oncogene 35, 1216–1224 (2016).
11. Venkatesan, H., Hoon, D. S. & Pantel, K. Circulating tumor DNA as liquid biopsy. Cancer. Clin. Oncol. 11, 426–437 (2011).
Persakis, S. & Speicher, M. R. Emerging concepts in liquid biopsies. *BMC Med.* **15**, 75 (2017).

Utz, P., Heitzer, E., Geigl, J. B. & Speicher, M. R. Patient monitoring through liquid biopsies using circulating tumor DNA. *Int. J. Cancer* **141**, 887–896 (2017).

Bach, D. H., Hong, J. Y., Park, H. J. & Lee, S. K. The role of exosomes and miRNAs in drug-resistant cancer of cells. *Int. J. Cancer* **141**, 220–230 (2017).

Belic, J. et al. Extracellular vesicle characterisation in cancer: cell-to-cell mediators of metastasis. *Cell Cancer Cell* **30**, 836–848 (2016).

Moore, C., Kosgodage, U., Lange, S. & Inal, J. M. The emerging role of exosome and microvesicle-(EMV)- based cancer therapeutic and immunotherapy. *Int. J. Cancer* **141**, 428–436 (2017).

Belic, J. et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS’ approach. *Clin. Chem.* **61**, 838–849 (2015).

Heidary, M. et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. *Breast Cancer Res. Treat.* **16**, 421 (2014).

Heitzer, E. et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with breast cancer. *Int. J. Cancer* **133**, 346–356 (2013).

Heitzer, E. et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. *Genome Med.* **5**, 30 (2013).

Mohan, S. et al. Changes in colorectal carcinoma genomes under Anti-EGFR therapy identified by whole-genome plasma DNA sequencing. *PloS Genet.* **10**, e1004271 (2014).

Utz, P. et al. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. *Nat. Commun.* **7**, 12008 (2016).

Heitzer, E. et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. *Cancer Res.** **73**, 2965–2975 (2013).

Aravanis, A. M., Lee, M. & Klausner, R. D. Next-generation sequencing of circulating tumor DNA for early cancer detection. *Cell* **168**, 571–574 (2017).

Vogelstein, B. et al. Cancer genome landscapes. *Science* **339**, 1546–1558 (2013).

Stroun, M. et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. *Oncology* **46**, 318–322 (1989).

Lo, Y. M. et al. Presence of fetal DNA in maternal plasma and serum. *Lancet* **350**, 485–487 (1997).

Chitty, L. S. & Lo, Y. M. Noninvasive prenatal screening for genetic diseases using cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. *Ultrasound Obstet. Gynecol.* **50**, 302–314 (2017).

Lo, Y. M. et al. Maternal plasma DNA sequencing reveals the genotype-wide genetic and mutational profile of the fetus. *Sci. Transl. Med.* **2**, 61ra49 (2010).

Canick, J. A., Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M. & Haddow, J. E. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. *Prenat. Diagn.* **33**, 667–674 (2013).

Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci. Transl. Med.* **6**, 224ra24 (2014).

Scudellari, M. The science myths that will not die. *Nature* **528**, 322–325 (2015).

Welch, H. G., Prorok, P. C., O’Malley, A. J. & Kramer, B. S. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. *N. Engl. J. Med.* **375**, 1438–1447 (2016).

Lannin, D. R. & Wang, S. Are small breast cancers good because they are small or small because they are good? *N. Engl. J. Med.* **376**, 2286–2291 (2017).

D’Andrea, E. et al. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. *Genet. Med.* **18**, 1171–1180 (2016).

Welch, H. G. & Robertson, D. J. Colorectal cancer on the decline—why screening can’t explain it all. *N. Engl. J. Med.* **374**, 1605–1607 (2016).

Meester, R. G. et al. Colorectal cancer deaths attributable to nonuse of screening in the United States. *Ann. Epidemiol.* **25**, 208e1–213 e1 (2015).

Landsorp-Vogelaar, I., van Ballegooijen, M., Zauber, A. G., Habbema, J. D. & Heitzer, E. The effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. *J. Natl. Cancer Inst.* **101**, 1412–1422 (2009).

Schymik, B. et al. Is there ‘progression through grade’ in ductal invasive breast cancer? *Breast Cancer Res. Treat.* **135**, 693–703 (2012).

Strum, W. B. Colorectal Adenomas. *N. Engl. J. Med.* **374**, 1065–1075 (2016).

Choi, Y., Sateia, H. F., Pears, K. S. & Stewart, R. W. Screening for colorectal cancer. *Semin. Oncol.* **44**, 34–44 (2017).

Tomasetti, C., Vogelstein, B. & Parmigiani, G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. *Proc. Natl. Acad. Sci. USA* **110**, 1999–2004 (2013).

Tomasetti, C. & Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science* **347**, 78–81 (2015).
87. Reineit, T. et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65, 625–634 (2016).
88. Sidransky, D. et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706–709 (1991).
89. Sidransky, D. et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256, 102–105 (1992).
90. Wang, Y. et al. Diagnostic potential of tumor DNA from ovarian cyst fluid. Elife 5, e15175 (2016).
91. Maritschnegg, E. et al. Lavage of the ureteric cavity for molecular detection of mullerian duct carcinomas: a proof-of-concept study. J. Clin. Oncol. 33, 4293–300 (2015).
92. Erickson, B. K. et al. Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet. Gynecol. 124, 881–885 (2014).
93. Kinde, I. et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 5, 167ra4 (2013).
94. Wang, Y. et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci. Transl. Med. 7, 293ra104 (2015).
95. Wang, Y. et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc. Natl. Acad. Sci. USA 112, 9704–9709 (2015).
96. Pan, W., Gu, W., Nagpal, S., Gephardt, M. H. & Quake, S. R. Brain tumor mutations detected in cerebral spinal fluid. Clin. Chem. 61, 514–522 (2015).
97. Chan, K. C. A. et al. Analysis of plasma Epstein-barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
98. Ambinder, R. F. Plasma Epstein-barr virus DNA for screening. N. Engl. J. Med. 377, 584–585 (2017).
99. Misale, S. et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra26 (2014).
100. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012).
101. Valtorta, E. et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int. J. Cancer 133, 1259–1265 (2013).
102. Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731–736 (2015).
103. Lehmann-Werman, R. et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl. Acad. Sci. U S A 113, E1826–E1834 (2016).
104. Guo, S. et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635–642 (2017).
105. Sun, K. et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl. Acad. Sci. USA 112, E5503–E5512 (2015).
106. Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57–68 (2016).
107. Ultsch, P. et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat. Genet. 48, 1273–1278 (2016).
108. Jiang, P. & Lo, Y. M. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet. 32, 360–371 (2016).
109. Jiang, P. et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci. USA 112, E1317–E1325 (2015).
110. Underhill, H. R. et al. Fragment length of circulating tumor DNA. PLoS Genet. 12, e1006162 (2016).
111. Burnham, P. et al. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Sci. Rep. 6, 27859 (2016).
112. Vong, J. S. L. et al. Single-stranded DNA library preparation preferentially enriches short maternal DNA in maternal plasma. Clin. Chem. 63, 1031–1037 (2017).
113. Moser, T. et al. Single-stranded DNA library preparation does not preferentially enrich circulating tumor DNA. Clin. Chem. 63, 151–161 (2017).
114. Schwarzenbach, H., Nishida, N., Calin, G. A. & Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11, 145–156 (2014).
115. Peinado, H., Lavotshkin, S. & Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21, 139–146 (2011).
116. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 (2007).
117. Best, M. G. et al. Swarn intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell 32, 238e9–252 e9 (2017).
118. Best, M. G. et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28, 666–676 (2015).
119. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105, 10513–10518 (2008).
120. Qi, P., Zhou, X. Y. & Du, X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol. Cancer 15, 39 (2016).
121. Wulfkuhle, J. D., Liotta, L. A. & Petricoin, E. F. Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3, 267–275 (2003).
122. Melo, S. A. et al. Gypsy 1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177–182 (2015).
123. Parekh, D. J. et al. A multi-institutional prospective trial in the USA confirms that the 4kscore accurately identifies men with high-grade prostate cancer. Eur. Urol. 68, 468–470 (2015).
124. Frantz, M. et al. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J. Proteom. 98, 44–58 (2014).
125. Schiffer, E. et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res. 15, 4935–4943 (2009).
126. Zimmerman, B. et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat. Diagn. 32, 1233–1241 (2012).
127. Rajagopalan, H., Nowak, M. A., Vogelstein, B. & Lengauer, C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 3, 695–701 (2003).
128. Walther, A. et al. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 9, 489–499 (2009).
129. Locker, G. Y. et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313–5327 (2006).
130. Porta-Pardo, E. et al. Comparison of algorithms for the detection of cancer drivers at subgenomic resolution. Nat. Methods 14, 782–788 (2017).
131. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).
132. Tokheim, C. J., Papadopoulos, N., Kinzler, K. W., Vogelstein, B. & Karchin, R. Evaluating the evaluation of cancer driver genes. Proc. Natl. Acad. Sci. USA 113, 14330–14335 (2016).
133. Davis, A., Gao, R. & Navin, N. Tumor evolution: linear, branching, neutral or punctuated? Biochim. Biophys. Acta 1867, 151–161 (2017).
134. Murtaza, M. et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 6, 8760 (2015).